Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corium Intl (CORI)

Corium Intl (CORI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corium Intl 235 CONSTITUTION DRIVE MENLO PARK CA 94025 USA

www.coriumgroup.com P: 650-298-8255

Description:

Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.

Key Statistics

Overview:

Market Capitalization, $K 459,650
Shares Outstanding, K 36,250
Annual Sales, $ 31,860 K
Annual Net Income, $ -47,790 K
Last Quarter Sales, $ 7,670 K
Last Quarter Net Income, $ -12,390 K
60-Month Beta 0.87
% of Insider Shareholders 30.80%

Growth:

1-Year Return 5.67%
3-Year Return 56.35%
5-Year Return 0.00%
5-Year Revenue Growth -25.66%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/29/18
Earnings Per Share ttm -1.57
EPS Growth vs. Prev Qtr 32.00%
EPS Growth vs. Prev Year 20.93%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CORI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -276.90%
Return-on-Assets % -57.52%
Profit Margin % -150.00%
Debt/Equity N/A
Price/Sales 12.60
Price/Cash Flow N/A
Price/Book 18.46
Book Value/Share -0.69
Interest Coverage -4.76
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar